Immune checkpoint inhibitors-associated myocarditis without cardiovascular symptoms

Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis

(2023) Joe-Elie Salem et al.   Cancer Discovery

A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer

(2023) Yue Hu et al.   BMC Pulmonary Medicine

Asymptomatic Myocarditis with Mild Cardiac Marker Elevation Following Nivolumab-Induced Myositis

(2022) Akito Shindo et al.   International Heart Journal

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

(2022) Alexander R Lyon et al.   EUROPEAN HEART JOURNAL

Immune Checkpoint Inhibitor–Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases

(2021) Ranjan Pathak et al.   ONCOLOGIST

Asymptomatic Immune Checkpoint Inhibitor-associated Myocarditis

(2020) Junya Tanabe et al.   INTERNAL MEDICINE

Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases

(2019) Suheil Albert Atallah-Yunes et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology

(2019) Dong-Yi Chen et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

(2018) Joe-Elie Salem et al.   LANCET ONCOLOGY